These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9288436)

  • 1. A possible new treatment approach to obsessive-compulsive disorder.
    Warneke L
    Can J Psychiatry; 1997 Aug; 42(6):667-8. PubMed ID: 9288436
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of obsessive-compulsive cutting behavior with naltrexone.
    Bystritsky A; Strausser BP
    J Clin Psychiatry; 1996 Sep; 57(9):423-4. PubMed ID: 9746454
    [No Abstract]   [Full Text] [Related]  

  • 3. Interactions of "ultra-low" doses of naltrexone and morphine in mature and young male and female rats.
    Hamann SR; Malik H; Sloan JW; Wala EP
    Recept Channels; 2004; 10(2):73-81. PubMed ID: 15204037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated mu-opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate-dependent rats.
    Van Bockstaele EJ; Rudoy C; Mannelli P; Oropeza V; Qian Y
    J Neurosci Res; 2006 Feb; 83(3):508-14. PubMed ID: 16385558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Documented effect of methadone, but not naltrexone].
    Heilig M
    Lakartidningen; 2002 Feb; 99(6):551-2. PubMed ID: 11881232
    [No Abstract]   [Full Text] [Related]  

  • 6. [Methadone and naltrexone in heroin addiction--an explanation from the SBU].
    Asplund K; Jonsson E
    Lakartidningen; 2002 Feb; 99(6):552-3. PubMed ID: 11881233
    [No Abstract]   [Full Text] [Related]  

  • 7. History of cocaine self-administration alters morphine reinforcement in the rat.
    Mierzejewski P; Stefanski R; Bienkowski P; Kostowski W
    Eur J Pharmacol; 2007 May; 562(1-2):77-81. PubMed ID: 17336286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonist treatment of opioid withdrawal translational low dose approach.
    Mannelli P; Gottheil E; Van Bockstaele EJ
    J Addict Dis; 2006; 25(2):1-8. PubMed ID: 16785213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone.
    Gade K; Häussinger C; Bandelow B
    Pharmacopsychiatry; 2009 Jul; 42(4):164-5. PubMed ID: 19585396
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid opioid detoxification.
    Brewer C; Gastfriend DR
    JAMA; 1998 Jun; 279(23):1872. PubMed ID: 9634251
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
    Webster LR; Brewer R; Wang C; Sekora D; Johnson FK; Morris D; Stauffer J
    J Pain Symptom Manage; 2010 Nov; 40(5):734-46. PubMed ID: 21075272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
    Koran LM; Cain JW; Dominguez RA; Rush AJ; Thiemann S
    Am J Psychiatry; 1996 Nov; 153(11):1450-4. PubMed ID: 8890679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need.
    Raffaeli W; Indovina P
    Pain Med; 2015 Jun; 16(6):1239-42. PubMed ID: 25643645
    [No Abstract]   [Full Text] [Related]  

  • 14. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study.
    Jones HE; Suess P; Jasinski DR; Johnson RE
    Am J Addict; 2006; 15(1):61-70. PubMed ID: 16449094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic treatment of obsessive compulsive disorders.
    Jenike MA
    Psychiatr Clin North Am; 1992 Dec; 15(4):895-919. PubMed ID: 1461804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buspirone in obsessive-compulsive disorder.
    Watts VS; Neill JR
    Am J Psychiatry; 1988 Dec; 145(12):1606. PubMed ID: 3195684
    [No Abstract]   [Full Text] [Related]  

  • 17. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder.
    Fallon BA; Campeas R; Schneier FR; Hollander E; Feerick J; Hatterer J; Goetz D; Davies S; Liebowitz MR
    J Neuropsychiatry Clin Neurosci; 1992; 4(1):70-5. PubMed ID: 1627966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiandrogenic treatment of obsessive-compulsive neurosis.
    Casas M; Alvarez E; Duro P; Garcia-Ribera C; Udina C; Velat A; Abella D; Rodriguez-Espinosa J; Salva P; Jané F
    Acta Psychiatr Scand; 1986 Feb; 73(2):221-2. PubMed ID: 2939692
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
    McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH
    Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.